DIHYDROCODEINE TRIFLUOROACETATE Property

Melting point:

112-113°

Boiling point:

bp15 248°

Density 

1.1412 (rough estimate)

refractive index 

1.5740 (estimate)

Flash point:

9℃

storage temp. 

2-8°C

solubility 

DMF: 20 mg/ml; DMF:PBS(pH 7.2)(1:1): 0.5 mg/ml; DMSO: 10 mg/ml

form 

A neat solid

EPA Substance Registry System

Morphinan-6-ol, 4,5-epoxy-3-methoxy-17-methyl-, (5?,6?)- (125-28-0)

Safety

Hazard Codes 

F,T

Risk Statements 

11-23/24/25-39/23/24/25

Safety Statements 

7-16-36/37-45

RIDADR 

UN1230 - class 3 - PG 2 - Methanol, solution

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Danger

Hazard statements

H225Highly Flammable liquid and vapour

H370Causes damage to organs

Precautionary statements

P210Keep away from heat/sparks/open flames/hot surfaces. — No smoking.

P260Do not breathe dust/fume/gas/mist/vapours/spray.

P280Wear protective gloves/protective clothing/eye protection/face protection.

P301+P310IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.

P311Call a POISON CENTER or doctor/physician.

DIHYDROCODEINE TRIFLUOROACETATE Chemical Properties,Usage,Production

Originator

Bicodein,Uquifa

Definition

ChEBI: Dihydrocodeine is a morphinane alkaloid.

Manufacturing Process

The codein was reduced by hydrogen in the presence catalyst Pt (or Pd, or Ni) and 7,8-dihydrocodein was obtained.
To the 7,8-dihydrocodein tartaric acid was added and mixed, in the result 7,8- dihydrocodein bitartrate was obtained.

Therapeutic Function

Antitussive, Narcotic analgesic

Safety Profile

Poison by ingestion, intravenous, and subcutaneous routes. Human systemic effects by ingestion and subcutaneous routes: somnolence, miosis (pupillary constriction), and respiratory depression. An analgesic. Can cause drug dependency with repeated doses. When heated to decomposition it emits toxic fumes of NOx. See also CODEINE.